Low Testosterone in Men Over 60: What's Normal, What Isn't, and What Helps
Age-related testosterone decline isn't automatically a disease, but symptomatic low T after 60 is common, treatable, and frequently overlooked.
— TL;DR
By 60, roughly one in three men has total testosterone below 300 ng/dL. Age alone isn't a reason to treat, but a symptomatic man with two morning readings below the range, a ruled-out prostate history, and reasonable cardiovascular health is a reasonable TRT candidate. The goal in this population is quality of life, bone density, and muscle preservation — not chasing 700 ng/dL numbers.
— Key takeaways
- About 30% of men over 60 have total testosterone below 300 ng/dL.
- The 2015 FDA advisory did not ban TRT in older men — it banned it as an anti-aging therapy in the absence of a diagnosis.
- Frailty, sarcopenia, and hip-fracture risk are the most underappreciated reasons to treat after 60.
- PSA velocity, hematocrit, and a cardiovascular screen are the three must-monitor metrics in this age group.
- Pellets and gels are often preferred over injections for men with needle aversion or bleeding issues on anticoagulants.
Disclosure. This page contains affiliate links. If you click through and make a purchase, we may earn a commission at no additional cost to you. Full disclosure
The Aging Testosterone Curve
Testosterone declines with age in an almost linear way after about 30 — roughly 1-2% per year. By 60, the average man has lost 30-40% of his peak testosterone. By 70, about half. This is normal aging. What's not automatically normal is the symptom burden that accompanies it in some men: frailty, loss of muscle mass, bone density loss, depression, cognitive fog, and significantly reduced quality of life.
For decades the medical consensus was "that's just getting older." The 2015 FDA advisory then swung hard the other way, discouraging TRT as an anti-aging therapy. Both positions miss the nuance. The question in a 65-year-old isn't "is his testosterone low for his age?" It's "is he symptomatic, is his low testosterone causing those symptoms, and is the benefit of treatment going to outweigh the risk?"
What Low T Actually Looks Like Past 60
The classic symptoms don't go away with age — they often get worse and get joined by new ones:
- Persistent fatigue not explained by sleep quality or medication
- Dramatic libido loss, often framed by men as "I just don't want to anymore"
- Muscle mass decline despite training — sarcopenia is the technical term
- Increased visceral fat with a simultaneous loss of lean mass
- Low mood, irritability, or flat affect
- Cognitive fog — word finding, short-term memory, executive function
- Sleep fragmentation — often worsened by obstructive sleep apnea
- Unexplained anemia — testosterone is a known stimulator of erythropoiesis
- Bone density loss — testosterone is essential for male skeletal health
- Frailty and falls — the practical endpoint nobody wants
The three symptom clusters that carry the most weight in a 60+ workup are libido + erectile change, loss of muscle/function, and unexplained mood change. If two of those are present, a hormone panel is defensible.
The 2023 TRAVERSE Trial Changed the Conversation
From 2015 through 2022, cardiovascular safety was the biggest open question in older-male TRT. The FDA required a manufacturer-funded trial. TRAVERSE enrolled 5,246 men aged 45-80 (mean 63), all with symptomatic hypogonadism and elevated cardiovascular risk, and randomized them to transdermal testosterone or placebo for a median of 22 months.
Key findings:
- No increased risk of major adverse cardiovascular events (MACE — heart attack, stroke, cardiovascular death)
- No increased risk of high-grade prostate cancer
- Small but real increases in pulmonary embolism, atrial fibrillation, and acute kidney injury
- Significant improvements in symptoms, bone density, and sexual function
This is the strongest cardiovascular safety evidence we have for TRT in older men. It doesn't clear everyone — it specifically matters for men with prior blood clots, A-fib, or uncontrolled cardiovascular disease. But it retired the broad "TRT is dangerous for the heart" position.
“The 2023 TRAVERSE trial followed 5,200+ men on TRT for two years and found no increase in heart attacks, strokes, or high-grade prostate cancer. It changed the conversation about TRT after 60.”
The Right Workup After 60
In addition to the standard hormone panel, men over 60 need:
- Two morning total testosterone readings (separated by at least 1 week)
- PSA and digital rectal exam at baseline and every 6-12 months
- Complete blood count — hematocrit > 54% usually triggers treatment pause or dose reduction
- Comprehensive metabolic panel, lipid panel, HbA1c
- Sleep apnea screen (STOP-BANG or similar) — treated before or alongside TRT
- Fracture/DEXA scan baseline if suspected osteopenia
Cardiovascular risk stratification using the pooled cohort equation is reasonable before starting, and men with prior DVT, PE, or A-fib should have an explicit discussion of alternatives (e.g., gels or pellets over injections, which produce more stable levels and possibly lower clot risk).
Which Delivery Method Makes Sense
Older men often benefit from the stability of pellets or gels over weekly injections. Practical considerations:
| Method | Pros for 60+ | Cons for 60+ |
|---|---|---|
| Weekly IM injection | Cheapest, titratable | Peaks and troughs, injection site pain, anticoagulant complication |
| Twice-weekly subcutaneous | Smoother levels, self-administered | Still requires a needle |
| Testosterone pellets | Every 3-6 months, stable levels | Minor surgical insertion; harder to adjust down quickly |
| Transdermal gels | Simplest, easy to stop | Skin transfer risk to family; variable absorption in thin older skin |
| Patches | Steady dosing | Frequent skin irritation |
Read the deep dive on pellets vs. injections if you're weighing the two most common options.
What to Monitor After Starting
In this age group, monitoring cadence should be tighter than in younger men:
- 6 weeks in: total T, free T, estradiol, hematocrit
- 3 months in: add PSA
- 6 months: PSA, DRE, hematocrit, lipid panel, symptom check
- Every 6 months thereafter: PSA, hematocrit; annual DEXA if baseline osteopenia; cardiovascular check-in
Red flags that warrant a pause or dose cut:
- Hematocrit > 54% (risk of stroke, clot)
- PSA rise > 1.4 ng/mL in 12 months or absolute PSA > 4.0
- New lower-extremity swelling (possible DVT)
- New chest pain or palpitations
- Worsening sleep apnea
The Fertility Conversation Usually Isn't the Constraint
For most men over 60, the fertility trade-off that dominates decision-making in younger men is moot. That simplifies the treatment menu — you don't need HCG or enclomiphene-only protocols purely to preserve sperm. You can pick the delivery method that best fits lifestyle, comorbidities, and cost.
Men 60-65 who do still want biological children (second marriages, delayed family) should still have the same enclomiphene-vs-TRT conversation as a 35-year-old.
Bottom Line
Low testosterone in men over 60 is common but not automatically benign, and age alone is not a reason to withhold treatment when symptoms are present, two morning readings are low, and the cardiovascular and prostate risks are reasonable. The 2023 TRAVERSE trial substantially loosened the safety concerns that dominated the 2015-2020 era, though specific risks around clotting and atrial fibrillation still require careful patient selection.
If you're 60+ and the description of "just getting older" is starting to include loss of function rather than just a slower mile time — a proper workup is worth the trouble. Treatment, if indicated, isn't about chasing 28-year-old numbers. It's about preserving muscle, bone, mood, and independence into the next two decades.
Sources
- Lincoff AM et al. "Cardiovascular Safety of Testosterone-Replacement Therapy." (TRAVERSE trial.) N Engl J Med, 2023.
- Basaria S et al. "Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels." JAMA, 2015.
- Snyder PJ et al. "Lessons From the Testosterone Trials." Endocr Rev, 2018.
- Bhasin S et al. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab, 2018.
- Corona G et al. "Testosterone Replacement Therapy and Cardiovascular Risk: A Review." World J Mens Health, 2024.
Frequently asked questions
Ready to get your testosterone checked?
At-home blood test, physician consultation, and treatment — starting at $99/month.
Get Started with PeterMD→Medical Disclaimer. This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any treatment. TRT requires a prescription from a licensed physician.
— Read next
TRT and Sleep Apnea: The Real Risk, and What to Do About It
Testosterone can worsen sleep apnea in men who have it. Here's the evidence, the risk factors, and what a responsible TRT screen looks like.
Read →Testosterone Pellets vs. Injections: Pros, Cons, and Real Cost
Pellets last 3-6 months and eliminate weekly injections — but they require a procedure and cost more. Here's when pellets win and when they don't.
Read →TRT Before and After: What to Realistically Expect
A realistic timeline of what changes to expect from TRT — from the first week through 12 months of treatment.
Read →